Foundayo (orforglipron) is an FDA-approved daily oral GLP-1 receptor agonist from Eli Lilly, launched in April 2026 for chronic weight management in check here adults with obesity or overweight. As a non-peptide small molecule, it works without food/water restrictions and showed up to 11.1% weight loss in 72-week trials.